Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Corcept Therapeutics Q2 2024 GAAP EPS $0.32 Beats $0.23 Estimate, Sales $163.800M Beat $155.226M Estimate

Author: Benzinga Newsdesk | July 29, 2024 04:12pm
Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.23 by 39.13 percent. The company reported quarterly sales of $163.800 million which beat the analyst consensus estimate of $155.226 million by 5.52 percent. This is a 39.15 percent increase over sales of $117.715 million the same period last year.

Posted In: CORT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist